Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
BUSINESS
Former Takeda CEO Yasuchika Hasegawa Dies at 80
Yasuchika Hasegawa, the former president and CEO of Takeda Pharmaceutical who helped transform the Japanese drug maker into a global pharmaceutical player, died on July 3 at the age of 80, the company said on September 11. Hasegawa joined Takeda…
To read the full story
Related Article
- Takeda Advisor Hasegawa, Herald of Takeda Globalization, Steps Down
July 1, 2019
- Takeda Chairman Hasegawa Officially Steps Aside as Adviser
June 29, 2017
- Takeda Chairman Hasegawa to Retire, Become Adviser in June
April 14, 2017
- Weber Becomes 1st Non-Japanese President of Takeda
June 27, 2014
- GSK Exec Tapped as Takeda’s Next President, 1st Non-Japanese to Lead Japan Juggernaut
December 2, 2013
BUSINESS
- Sanofi’s ITP Drug Wayrilz Goes on Sale in Japan
October 21, 2026
- Maruho Secures South Korean Rights to Incyte’s Ruxolitinib Cream
October 21, 2026
- CMIC Turns to AI to Hear Job Applicants in Their Own Words
October 21, 2026
- Arthur D. Little Urges Pricing Revamp to Spur Regenerative Medicine in Japan
October 21, 2026
- Entyvio PIV Trial Links Disease Clearance to 70% Lower UC Complication Risk
October 21, 2026
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…